The U.S. gastrointestinal surgery procedures market size was valued at USD 18.9 billion in 2025 and is projected to grow from USD 19.5 billion in 2026 to USD 24.4 billion by 2033, at a CAGR of 3.2% from 2026 to 2033. The market is supported by the large and continuing burden of digestive diseases, which creates a substantial need for surgical diagnosis and treatment.
Gastrointestinal conditions such as colorectal cancer, inflammatory bowel disease, diverticular disease, gallbladder disorders, and obesity-related digestive complications contribute to the demand for procedures across hospitals and ambulatory surgical centers. Colorectal cancer remains an important contributor to gastrointestinal surgical demand; according to the latest CDC data, 155,662 new colorectal cancer cases were reported in the U.S. in 2023, while 54,468 people died from colorectal cancer in 2024. The continued disease burden supports demand for procedures such as colectomy, bowel resection, rectal surgery, cholecystectomy, and other abdominal surgeries. The increasing prevalence of obesity is another important driver, particularly for bariatric and metabolic gastrointestinal procedures.
CDC data show that 40.3% of U.S. adults had obesity during August 2021-August 2023, while 2024 surveillance found that every U.S. state and territory had an adult obesity prevalence of at least 25%. The high obesity burden increases the patient population eligible for surgical weight-management procedures and is also associated with several conditions that can require gastrointestinal or abdominal surgery. As a result, the continued prevalence of obesity is expected to support demand for procedures such as sleeve gastrectomy and gastric bypass, while also increasing the need for surgical management of related gastrointestinal and hepatobiliary conditions.
The shift toward minimally invasive and robotic-assisted surgery is further strengthening market growth. Laparoscopic and robotic approaches are increasingly used for colorectal, bariatric, gallbladder, and other abdominal procedures because they can provide smaller incisions, improved visualization, greater instrument control, and potentially faster recovery compared with conventional open surgery. This trend is being reinforced by continued investment in robotic surgical platforms. For example, the FDA granted De Novo authorization for Johnson & Johnson MedTech's OTTAVA Robotic Surgical System on July 21, 2026, adding another robotic platform to the U.S. surgical market. The increasing availability of advanced robotic and laparoscopic technologies is therefore expanding technology options for hospitals and surgeons and supporting the transition toward minimally invasive gastrointestinal procedures.
Government-supported colorectal cancer screening is also indirectly supporting the gastrointestinal surgery ecosystem by encouraging earlier detection and treatment of colorectal disease. CMS continues to cover colorectal cancer screening as a Medicare preventive service, including screening colonoscopy and other approved screening tests. Earlier identification of colorectal abnormalities can lead to additional diagnostic evaluation and, when cancer or advanced disease is identified, surgical treatment. This creates a pathway from screening and diagnosis to surgical management, supporting continued demand for colorectal procedures in the U.S.
Gastrointestinal conditions such as colorectal cancer, inflammatory bowel disease, diverticular disease, gallbladder disorders, and obesity-related digestive complications contribute to the demand for procedures across hospitals and ambulatory surgical centers. Colorectal cancer remains an important contributor to gastrointestinal surgical demand; according to the latest CDC data, 155,662 new colorectal cancer cases were reported in the U.S. in 2023, while 54,468 people died from colorectal cancer in 2024. The continued disease burden supports demand for procedures such as colectomy, bowel resection, rectal surgery, cholecystectomy, and other abdominal surgeries. The increasing prevalence of obesity is another important driver, particularly for bariatric and metabolic gastrointestinal procedures.
CDC data show that 40.3% of U.S. adults had obesity during August 2021-August 2023, while 2024 surveillance found that every U.S. state and territory had an adult obesity prevalence of at least 25%. The high obesity burden increases the patient population eligible for surgical weight-management procedures and is also associated with several conditions that can require gastrointestinal or abdominal surgery. As a result, the continued prevalence of obesity is expected to support demand for procedures such as sleeve gastrectomy and gastric bypass, while also increasing the need for surgical management of related gastrointestinal and hepatobiliary conditions.
The shift toward minimally invasive and robotic-assisted surgery is further strengthening market growth. Laparoscopic and robotic approaches are increasingly used for colorectal, bariatric, gallbladder, and other abdominal procedures because they can provide smaller incisions, improved visualization, greater instrument control, and potentially faster recovery compared with conventional open surgery. This trend is being reinforced by continued investment in robotic surgical platforms. For example, the FDA granted De Novo authorization for Johnson & Johnson MedTech's OTTAVA Robotic Surgical System on July 21, 2026, adding another robotic platform to the U.S. surgical market. The increasing availability of advanced robotic and laparoscopic technologies is therefore expanding technology options for hospitals and surgeons and supporting the transition toward minimally invasive gastrointestinal procedures.
Government-supported colorectal cancer screening is also indirectly supporting the gastrointestinal surgery ecosystem by encouraging earlier detection and treatment of colorectal disease. CMS continues to cover colorectal cancer screening as a Medicare preventive service, including screening colonoscopy and other approved screening tests. Earlier identification of colorectal abnormalities can lead to additional diagnostic evaluation and, when cancer or advanced disease is identified, surgical treatment. This creates a pathway from screening and diagnosis to surgical management, supporting continued demand for colorectal procedures in the U.S.
U.S. Gastrointestinal Surgery Procedures Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. gastrointestinal surgery procedures market report based on CPT, indication, procedure urgency, and end use:CPT Outlook (Revenue, USD Billion, 2021 - 2033)
- 43020-43135, 43279-43499
- 44005-44346, 44500-44799, 44800-44899, 44900-44979, 45000-45190, 45395-45999, 46020-46505, 46700-46999
- 47010-47399, 47400-47480, 47562-47999, 48020, 48105-48160, 48500-48999
- 43644-43645; 43770-43775; 43845-43848; 43886-43888
Indication Outlook (Revenue, USD Billion, 2021 - 2033)
- Cancer
- Benign GI Disorders
- Acute/Emergency Conditions
- Obesity
- Other Conditions
Procedure Urgency Outlook (Revenue, USD Billion, 2021 - 2033)
- Elective
- Urgent
- Emergency
End Use Outlook (Revenue, USD Billion, 2021 - 2033)
- Hospitals
- Ambulatory Surgical Centers
- Specialty Surgical Centers
- Other
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Gastrointestinal Surgery Procedures Market Variables, Trends & Scope
Chapter 4. U.S. Gastrointestinal Surgery Procedures Market: CPT Estimates & Trend Analysis
Chapter 5. U.S. Gastrointestinal Surgery Procedures Market: Indication Estimates & Trend Analysis
Chapter 6. U.S. Gastrointestinal Surgery Procedures Market: Procedure Urgency Estimates & Trend Analysis
Chapter 7. U.S. Gastrointestinal Surgery Procedures Market: End Use Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Johnson & Johnson MedTech/Ethicon
- Medtronic
- Stryker
- Intuitive Surgical
- CONMED
- Applied Medical
- B. Braun
- Teleflex
- Olympus
- KARL STORZ
- BD
- Cook Medical
- W. L. Gore & Associates
- Integra LifeSciences
- Zimmer Biomet
